Home Depot kicked off this week's string of retailer earnings reports. Novo Nordisk provided two major updates on its blockbuster weight-loss drugs. Ukraine President Volodymyr Zelenskyy and European leaders met with President Donald Trump.

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended this month. Novo Nordisk faces near-term challenges from semaglutide compounders and Eli Lilly, but the recent FDA approval for MASH and international expansion offer new growth avenues.

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease. Shares climbed roughly 4.5% in Denmark (read more about [weight-loss drugs' s

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Novo Nordisk A/S innovation and growth continue to shine. Now, it has a partnership with GoodRX Holdings. Click for my updated look at NVO post Q2 earnings.